IMMUNOCORE HOLDINGS PL

Immunocore to present at upcoming investor conferences

08 نوفمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Immunocore reports third quarter financial results and provides a business update

06 نوفمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

14 سبتمبر 2024 03:00:00 بحسب Nasdaq GlobeNewswire

Immunocore to present at the 2024 Cantor Global Healthcare Conference

12 سبتمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Immunocore announces transition of Chief Financial Officer

29 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Immunocore reports second quarter financial results and provides a business update

08 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Immunocore to report second quarter 2024 financial results and host call on August 8, 2024

01 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

18 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

01 يونيو 2024 07:59:59 بحسب Nasdaq GlobeNewswire

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

31 مايو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Immunocore to present at the Jefferies Global Healthcare Conference

30 مايو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

29 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Immunocore reports first quarter financial results and provides a business update

08 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Immunocore announces upcoming presentation and posters at ASCO 2024

24 أبريل 2024 10:00:00 بحسب Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

04 أبريل 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Immunocore presented two posters at CROI 2024

05 مارس 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

01 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

28 فبراير 2024 07:34:03 بحسب Nasdaq GlobeNewswire

Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial

22 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

21 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire